The lower-airway microbiome and metabolome in preterm infants: Identifying

2 potential predictive biomarkers of bronchopulmonary dysplasia

- 3 Qi Xu<sup>2</sup>, Jialin Yu<sup>1</sup>\*, Junli He<sup>1</sup>, <sup>3</sup>, Yu He<sup>3</sup>,
- <sup>1</sup>Department of Neonatology, Shenzhen University General Hospital, Shenzhen,
- 5 China

1

9

13

- <sup>2</sup>Children's Hospital, Capital Institute of Pediatrics, Beijing, China
- <sup>3</sup>Department of Neonatology, Children's Hospital of Chongqing Medical University,
- 8 Chongqing, China
- 10 Correspondence: Jialin Yu
- 11 Email address: yujialin486@126.com
- Post address: No. 1098, Xueyuan Avenue, Xili University Town, Shenzhen, China

## 14 Abstract

- The lower-airway microbiome may influence the pathogenesis of lung disease.
- Bronchopulmonary dysplasia (BPD) is a serious morbidity associated with preterm
- birth that may be influenced by lower-airway microbial or metabolic alterations. This
- study used16S rRNA gene sequencing, metabolomic analyses, and the Kyoto
- 19 Encyclopedia of Genes and Genomes (KEGG) database to investigate the
- 20 lower-airway microbiome and metabolome in a cohort of preterm infants with mild,
- 21 moderate, or severe BPD or no BPD. Differences in the diversity and composition of
- the infants' lower airway microbiota, as well as metabolic status, were initially
- observed, but became less pronounced at 7 days of life. Decreased diversity of the
- 24 lower-airway microbiome, increased abundance of *Stenotrophomonas*, and increased
- level of sn-glycerol 3-phosphoethanolamine were associated with increased BPD
- severity, and have potential as predictive biomarkers for BPD. Stenotrophomonas may
- 27 contribute to the development of BPD and influence the composition of the
- lower-airway microbiome through its metabolite, sn-glycerol 3-phosphoethanolamine.
- 29 These findings provide novel insights into the lower-airway microbiome and its role
- 30 in BPD.

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

The lower-airway microbiome and metabolome in preterm infants: Identifying potential predictive biomarkers of bronchopulmonary dysplasia Qi Xu<sup>2</sup>, Jialin Yu<sup>1</sup>\*, Junli He<sup>1</sup>, Qi Tan<sup>3</sup>, Yu He<sup>3</sup>, <sup>1</sup>Department of Neonatology, Shenzhen University General Hospital, Shenzhen, China <sup>2</sup>Children's Hospital, Capital Institute of Pediatrics, Beijing <sup>3</sup>Department of Neonatology, Children's Hospital of Chongging Medical University, Chongqing, China Abstract The lower-airway microbiome may influence the pathogenesis of lung disease. Bronchopulmonary dysplasia (BPD) is a serious morbidity associated with preterm birth that may be influenced by lower-airway microbial or metabolic alterations. This study used16S rRNA gene sequencing, metabolomic analyses, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to investigate the lower-airway microbiome and metabolome in a cohort of preterm infants with mild, moderate, or severe BPD or no BPD. Differences in the diversity and composition of the infants' lower airway microbiota, as well as metabolic status, were initially observed, but became less pronounced at 7 days of life. Decreased diversity of the lower-airway microbiome, increased abundance of Stenotrophomonas, and increased level of sn-glycerol 3-phosphoethanolamine were associated with increased BPD severity, and have potential as predictive biomarkers for BPD. Stenotrophomonas may contribute to the development of BPD and influence the composition of the lower-airway microbiome through its metabolite, sn-glycerol 3-phosphoethanolamine. These findings provide novel insights into the lower-airway microbiome and its role in BPD. **Key words:** BPD, microbiome, genomics, metabonomic

## 1. Introduction

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

Bronchopulmonary dysplasia (BPD) is a serious morbidity associated with preterm birth that affects an estimated 50% of infants born at < 28 weeks of gestation [1]. Infants with BPD have an increased risk of mortality during the first year. Those who survive may suffer long-term pulmonary impairment and abnormal neurodevelopment, which can result in substantial healthcare resource utilization and cost [2]. Risk factors for BPD include, but are not limited to, gestational age at birth, impaired growth for gestational age, low infant birth weight, infectious exposures, barotrauma, oxygen exposure, and environmental cigarette smoke [3]. Evidence from epidemiological data, clinical data, and animal models indicate a key role for the microbiome in lung disease [4-6], and indicate that the lower-airway microbiome is altered in multiple respiratory disorders [7, 8]. Some reports show that the lower-airway microbiome is present at birth, and microbial dysbiosis may be associated with BPD [9, 10]. However, by now the related research is rare and the present results differ from each other, so it needs further research. What's more, the mechanisms by which the microbiome alterations lead to BPD have never been addressed. Gut microbiota is associated with a variety of human diseases through metabolites [11]. We hypothesized that lower-airway microbial metabolism plays a role in the pathogenesis of BPD. In this prospective observational cohort study, tracheal aspirates (TA) were collected during mechanical ventilation of infants to investigate 1) the lower-airway microbiome at birth (Day 1) and on Day 7 after birth; 2) the lower-airway metabolomic signatures at birth and on Day 7 after birth; and 3) the relationship between differential metabolites and specific bacteria among infants with severe BPD, moderate BPD, mild BPD, and no BPD. 2. Methods This prospective observational cohort study was conducted at the Neonatal Intensive Care Unit of the Children's Hospital of Chongqing Medical University between October 2017 and July 2018. The Institutional Review Board of Chongqing

91 Medical University approved the protocol. Informed consent was received from the 92 parents or guardians of all participants. The study was performed in accordance with approved guidelines. 93 94 2.1 Patient population and clinical data collection 95 Infants born at <34 weeks gestation that underwent endotracheal intubation and mechanical ventilation in the first 24 \( \text{h} \) of life and remained intubated until at least 96 Day 7 after birth were included in this study. Exclusion criteria were: 1) clinical 97 evidence of congenital heart disease (except patent ductus arteriosus [PDA], patent 98 99 foramen ovale [PFO] or atrial septal defect [ASD] < 1cm, or ventricular septal defect 100 [VSD] < 2mm if known prior to enrollment); 2) lethal congenital abnormality; 3) 101 congenital sepsis; 4) evidence of pulmonary hypoplasia; or 5) futile cases (anticipated 102 death prior to hospital discharge) [10]. 103 Infants were divided into four groups stratified by the diagnosis and severity of 104 BPD: severe BPD, moderate BPD, mild BPD, and no BPD. BPD was diagnosed 105 based on the need for supplemental oxygen at 28 days of age [12, 13]. BPD status and 106 severity was assessed at 36 weeks postmenstrual age according to the National 107 Institutes of Health workshop definition [13]. Late onset sepsis was defined as a 108 positive blood culture after 72 h of life. 109 Clinical data were collected from a review of electronic medical records at study 110 enrollment and during hospitalization. Information on maternal history, delivery, and 111 clinical assessments was recorded. 112 2.2 Sample collection 113 Tracheal aspirates (TA) were collected during mechanical ventilation at birth 114 (Day 1) and on Day 7 after birth according to a previously published protocol [13-15]. 115 Briefly,  $0.5 \square$  ml of sterile isotonic saline was instilled into the infants' endotracheal 116 tubes. Infants were manually ventilated through their endotracheal tube for three 117 breaths using a bag-mask, and fluid was suctioned into a sterile mucus trap [14]. 118 Samples were divided into 2 aliquots for extraction of bacterial DNA or metabolomics research and frozen at -80°C until further processing. 119

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

2.3 Isolation of microbial DNA, creation of 16S V4 amplicon library, and DNA sequencing Microbial genomic DNA from each sample was isolated and purified. The V4 region of the 16S rRNA gene from the microbial DNA was amplified using a polymerase chain reaction (PCR) with unique bar coded primers to create an "amplicon library" [16]. The library was sequenced using the Illumina MiSeq platform and subsequently quantified (KAPA Library Quantification Kit KK4824), according to the manufacturer's instructions. 2.4 Profiling of 16S rRNA gene sequencing data Raw sequences were processed with the Quantitative Insights into Microbial Ecology (QIIME) 1.8.0 pipeline1. The concat function was used to combine reads into tags according to an overlapping relationship. Reads from each sample were separated with barcodes, and low quality reads were removed. Processed tags were clustered at 97% similarity into operational taxonomic units (OTUs). Taxonomy was assigned to OTUs by matching to the Greengenes database (Release 13.8)2. Alpha diversity analyses (Shannon index) and beta diversity analyses (principal coordinate analysis [PCoA]) were performed. 2.4 Metabolomics analysis based on UHPLC-Q-TOF/MS TA samples were analyzed using an ultra-high-performance liquid chromatography (UHPLC) system (1290 Infinity LC, Agilent Technologies) coupled to a quadrupole time-of-flight mass spectrometer (AB Sciex TripleTOF 6600) at Shanghai Applied Protein Technology Co., Ltd. Samples were thawed at 4°C and 100 μL aliquots were mixed with 400 μL of cold methanol/acetonitrile (1:1, v/v) to remove the protein. After centrifuging for 15 min (14000g, 4 °C), the supernatant was dried in a vacuum centrifuge. For liquid chromatography-mass spectrometry (LC-MS), samples were dissolved in 100 µL acetonitrile/water (1:1, v/v). Pooled quality control (QC) samples were used to monitor the stability and repeatability of instrument analysis. The QC samples were inserted regularly and analyzed in every 5 samples.

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

and analyzed for non-linear retention time (RT) alignment, peak detection, and filtration. 2.5 Profiling of metabolomics data Processed data were normalized to total peak intensity, imported into SIMCA-P (version 14.1, Umetrics, Umea, Sweden), and analyzed using Pareto-scaled principal component analysis (PCA) and orthogonal partial least-squares discriminant analysis (OPLS-DA). The variable importance in the projection (VIP) value for each variable in the OPLS-DA model was calculated to indicate its contribution to the classification. One-way ANOVA was used to determine the significance of each metabolite with a VIP value >1. P<0.05 were considered statistically significant. Discriminatory metabolites within the data set were visualized as heat maps, which were generated using a hierarchical clustering algorithm. Molecules associated with significant changes were searched against the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.jp/kegg/pathway.html). 2.6 Statistical analysis Statistical analysis was performed using SPSS version 22.0 for Windows (SPSS Inc., USA). Normally distributed data are expressed as mean  $\pm$  SD; non-normally distributed data are expressed as median and interquartile range (IQR). Between group differences were analyzed with Fisher's Exact test for categorical variables and Kruskal-Wallis test for continuous variables after subsampling. Pairwise comparison was performed with White's non-parametric t-test. Correlations between microbiome-related metabolites and bacterial species were evaluated using Pearson's correlation coefficient. P < 0.05 was considered statistically significant. 3.0 Results 3.1 Demographic and clinical characteristics of the enrolled patients This study included 30 premature infants divided into 4 groups, including 10 infants with severe BPD, 5 infants with moderate BPD, 10 infants with mild BPD, and 5 infants with no BPD. The demographic and clinical characteristics of the included infants are shown in **Table 1.** There were no significant differences in the

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

demographic and clinical characteristics between the groups, except for number of hours of mechanical ventilation and number of days of antibiotics. 3.2 Diversity and composition of the lower-airway microbiome The Shannon index was significantly lower at birth (Day 1) (P=0.0019; Figure **1a**) and on Day 7 after birth (P=0.016; **Figure 1b**) in infants with BPD compared to no BPD. The difference was more pronounced on Day 1 and was negatively correlated with the severity of BPD. Principal coordinates analysis (PCoA) showed a significant difference in the bacterial composition of the lower-airway microbiome at birth (Day 1) between the four groups (**Figure 1c**), and a less distinct difference on Day 7 after birth (**Figure 1d**). At the phylum level, *Proteobacteria* was dominant in the lower-airway microbiome of all infants at birth (Day 1) (**Figure 1e**) and on Day 7 after birth (**Figure 1f**), and there were no significant differences in the composition of the lower-airway microbiome between the four groups. At the genus level, the composition of the lower-airway microbiome was significantly different between groups at birth (Day 1). Stenotrophomonas was more abundant in infants with BPD compared to no BPD, and abundance was positively correlated with the severity of disease (P < 0.05) (**Figure 2a**). Findings on Day 7 after birth were similar, but not statistically significant (*P*=0.064) (**Figure 2b**). 3.3 Metabolomic analysis of tracheal aspirates (TA) TAs were subjected to LC/MS analysis in positive ion mode (ES+) and negative ion mode (ES-). Principle component analysis (PCA) was performed to reduce dimensionality in the dataset (**Figure 3a, b**). Hierarchical clustering heat maps visualized patterns in molecular data across groups (**Figure 3c-f**). There were significant differences in 63 metabolites, including 23 in ES- and 40 in ES+ (Figure 3c,d), between the four groups at birth (Day 1), and 29 metabolites, including 11 in ES- and 18 in ES+, on Day 7 after birth (**Figure 3e-f**). Among these metabolites, sn-glycerol 3-phosphoethanolamine was positively correlated with BPD severity at birth (Day 1) (**Figure 4**), but not on Day 7 after birth.

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

3.4 Correlation between the lower-airway microbiome and metabolites Pearson's correlation coefficient was used to explore the functional correlation between the changes in the lower-airway microbiome and differences in metabolites across the four groups at birth (Day 1) (**Figure 5**). There was a significant positive correlation between the abundance of *Stenotrophomonas* and sn-glycerol 3-phosphoethanolamine levels (r=0.45) (P<0.05). **Discussion** Studies investigating the correlation between BPD and the lower-airway microbiome in infants are scarce, and there remains an unmet clinical need to describe the lower-airway microbial communities and lower-airway metabolomic signatures in patients with BPD. Findings will allow the identification of microbial biomarkers for early detection of BPD and further understanding of the pathophysiology of BPD. The present study used16S rRNA gene sequencing, metabolomic analyses, and the KEGG database in attempt to fill these evidence gaps. Results showed that multiple bacterial taxa can be identified in the respiratory secretions of intubated premature infants, even at birth and prior to surfactant administration. The diversity and composition of the lower-airway microbiome in infants with and without BPD varied at birth, but the differences became less pronounced on Day 7 of life. Consistent with a previous report, our study showed lower diversity in the lower-airway microbiome of infants that developed BPD [14]. Our results also revealed that alpha diversity of lower-airway communities was negatively correlated with BPD severity. At the phylum level, there were no significant differences in the composition of the lower-airway microbiome in infants with and without BPD or according to BDP severity. Proteobacteria was the most abundant microbe in all infants. These data align with one previous report, [14], but differ from another, which found that Staphylococcus and Ureaplasma were the most dominate lower-airway microbes in infants in their institution [10]. These disparate findings may be due to different environments, which likely influenced the composition of the lower-airway

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

in infants with BPD compared to no BPD, and the abundance of Stenotrophomonas was positively correlated with BPD severity. These findings suggest that decreased diversity of the lower-airway microbiome and increased abundance of Stenotrophomonas in the lower-airway microbial community of intubated premature infants have potential as microbial biomarkers for early detection of BPD. Stenotrophomonas is a nosocomial opportunistic pathogen of the Xanthomonadaceae family [17]. Stenotrophomonas isolated from the environment or in the clinical setting exhibits resistance to antibiotics and stress and forms biofilms on various surfaces, including the abiotic surfaces of catheters and prosthetic devices [18, 19]. Stenotrophomonas colonizes the lungs of patients with cystic fibrosis and those who are immunocompromised, and may represent a marker of chronic lung disease [18, 20-22]. Stenotrophomonas can influence the spatial organization and thus the function and composition of complex microbiomes [23, 24]. Data from the present study suggest a role for Stenotrophomonas in the pathogenesis of BPD in intubated premature infants. As the composition of the lower-airway microbiome in preterm infants varied with the presence or absence of BPD and with BPD severity, we characterized the lower-airway metabolome in these infants. Findings showed significant differences between infants in 63 metabolites at birth (Day 1) and 29 metabolites on Day 7 of life, implying that metabolite variation paralleled that of the lower-airway microbiome. Among these metabolites, sn-glycerol 3-phosphoethanolamine was positively correlated with BPD severity, identifying it as a potential metabolic biomarker for early detection of BPD. The KEGG database showed that sn-glycerol 3-phosphoethanolamine has a role in glycerophospholipid metabolism. Glycerophospholipid has structural functions in bacteria, facilitates bacterial adaptation to environmental conditions, and is involved in bacteria-host interactions [28]. Glycerophospholipid is also associated with the pathophysiology of chronic obstructive pulmonary disease (COPD) [29]. These findings suggest that sn-glycerol 3-phosphoethanolamine may affect lower-airway microbiome composition and respiratory health in preterm infants. Our findings also identified a significant positive

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292293

294

295

296

297

298

299

correlation between the abundance of *Stenotrophomonas* and sn-glycerol 3-phosphoethanolamine levels, an association that was confirmed with the KEGG database. This indicates that *Stenotrophomonas* may be abundant in the lower-airway microbiome of infants with BPD and responsible for the production of sn-glycerol 3-phosphoethanolamine, which may act as a pathogenic signal in these patients. To the author's knowledge, this prospective study is the first to identify a microbiome-metabolome signature in preterm infants with BPD. However, this study had several limitations. First, the sample size was small. Second, the data did not provide evidence that the lower-airway microbiome directly contributed to BPD. Although it will be challenging to determine a causal relationship between the lower-airway microbiome, metabolites and BPD development, further investigations are warranted. In summary, there were significant differences in the diversity and composition of the lower-airway microbiome and metabolome in preterm infants with severe, moderate, or mild BPD or no BPD; the differences were more pronounced at birth (Day 1) than on Day 7 of life. Decreased diversity of the lower-airway microbiome, increased abundance of Stenotrophomonas, and increased level of sn-glycerol 3-phosphoethanolamine were positively associated with BPD severity, and have potential as predictive biomarkers for BPD. Stenotrophomonas may contribute to the development of BPD and influence the composition of the lower-airway microbiome through its metabolite, sn-glycerol 3-phosphoethanolamine. These findings provide novel insights into the lower-airway microbiome and its functions in BPD. Funding: National Natural Science Foundation of China Fund Project (No. 81571483, 81971431), Shenzhen Science and Technology Innovation Free Exploration Project (JCYJ20170817100735621), Shenzhen Synthetic Biology Innovation Research Institute, Chinese Academy of Sciences, Opening to the Outside World Fund Project (DWKF20190008), Scientific Research Fund of Shenzhen University General Hospital (SUGH2020QD003).

300 **Competing interests:** There are no ethical/legal or financial conflicts involved in the 301 article. 302 303 **References:** 304 Onland W, Cools F, Kroon A, et al. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days 305 After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants 306 Receiving Mechanical Ventilation: A Randomized Clinical Trial [J]. JAMA, 2019, 321(4): 307 354-363. 308 [2] Erik A. Jensen MM, Kevin Dysart, MD1, Marie G. Gantz, PhD2, Scott McDonald BS2, Nicolas A. 309 Bamat, MD MSCE1, Martin Keszler, MD3; Haresh Kirpalani, BM MSc1; Matthew M. Laughon, 310 MD MPH4; Brenda B. Poindexter, MD MS5; Andrea F. Duncan, MD MS6; Bradley A. Yoder, 311 MD7; Eric C. Eichenwald, MD1, Sara B. DeMauro, MD MSCE. The Diagnosis of 312 Bronchopulmonary Dysplasia in Very Preterm Infants: An Evidence-Based Approach [J]. Am J 313 Respir Crit Care Med, 2019, doi: 10.1164/rccm.201812-2348OC( 314 [3] Bradley Wallace M, Amelie Peisl, BS,, Gregory Seedorf B, Taylor Nowlin, BS, Christina Kim, MD, 315 Jennifer Bosco, PhD, Jon Kenniston, PhD, Dennis Keefe, PhD, and Steven H. Abman M. 316 Anti-sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of BPD 317 [J]. American journal of respiratory and critical care medicine, 2018, 197(6): 776-787. 318 [4] Remot A, Descamps D, Noordine ML, et al. Bacteria isolated from lung modulate asthma 319 susceptibility in mice [J]. ISME J, 2017, 11(5): 1061-1074. 320 [5] Pammi M, Lal CV, Wagner BD, et al. Airway Microbiome and Development of 321 Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review [J]. J Pediatr, 2019, 322 204(126-133 e122. 323 [6] Francisco Casado REM. The emergence of preclinical studies on the role of the microbiome in 324 lung development and experimental animal models of bronchopulmonary dysplasia [J]. Am J 325 Physiol Lung Cell Mol Physiol, 2020, Ubags NDJ and Marsland BJ. Mechanistic insight into the function of the microbiome in lung 326 [7] 327 diseases [J]. Eur Respir J, 2017, 50(3): 328 [8] Tracy M, Cogen J and Hoffman LR. The pediatric microbiome and the lung [J]. Curr Opin 329 Pediatr, 2015, 27(3): 348-355. 330 Lal CV, Travers C, Aghai ZH, et al. The Airway Microbiome at Birth [J]. Sci Rep, 2016, 6(31023. [9] 331 [10] Wagner BD, Sontag MK, Harris JK, et al. Airway Microbial Community Turnover Differs by BPD 332 Severity in Ventilated Preterm Infants [J]. PLoS One, 2017, 12(1): e0170120. 333 [11] Vojinovic D, Radjabzadeh D, Kurilshikov A, et al. Relationship between gut microbiota and 334 circulating metabolites in population-based cohorts [J]. Nat Commun, 2019, 10(1): 5813. 335 [12] Kjellberg M, Bjorkman K, Rohdin M, et al. Bronchopulmonary dysplasia: clinical grading in 336 relation to ventilation/perfusion mismatch measured by single photon emission computed 337 tomography [J]. Pediatr Pulmonol, 2013, 48(12): 1206-1213. 338 [13] BANCALARI AHJaE. Bronchopulmonary Dysplasia [J]. American journal of respiratory and 339 critical care medicine, 2001, 163(7): 1723-1729. 340 [14] Lohmann P, Luna RA, Hollister EB, et al. The airway microbiome of intubated premature 341 infants: characteristics and changes that predict the development of bronchopulmonary

342		dysplasia [J]. Pediatr Res, 2014, 76(3): 294-301.
343	[15]	Mourani PM, Harris JK, Sontag MK, et al. Molecular identification of bacteria in tracheal
344		as pirate fluid from mechanically ventilated preterm infants [J]. PLoS One, 2011, 6(10):
345		e25959.
346	[16]	Lu K, Abo RP, Schlieper KA, et al. Arsenic exposure perturbs the gut microbiome and its
347		metabolic profile in mice: an integrated metagenomics and metabolomics analysis [J].
348		Environ Health Perspect, 2014, 122(3): 284-291.
349	[17]	Ryan RP, Monchy S, Cardinale M, et al. The versatility and adaptation of bacteria from the
350		genus Stenotrophomonas [J]. Nat Rev Microbiol, 2009, 7(7): 514-525.
351	[18]	An SQ and Berg G. Stenotrophomonas maltophilia [J]. Trends Microbiol, 2018, 26(7): 637-638.
352	[19]	David Skurnik1; Michael R. Davis JDBKLMCCDRDCTRLWTM-L, Vargas5; CCRHTRMELTSO and
353		Alexander J. McAdam6; Tami D. Lieberman7; Roy Kishony7 JJL, 10; Gerald B. Pier;Joanna B.
354		Goldberg2; Gregory P. Priebe1,3. Targeting pan-resistant bacteria with antibodies to a broadly
355		conserved surface polysaccharide expressed during infection [J]. Journal of Infectious
356		Diseases, 2012, 205(11): 1709-1718.
357	[20]	Lisa C Crossman VCG, J Maxwell Dow, Georgios S Vernikos, Aki Okazaki, Mohammed Sebaihia,
358		David Saunders, Claire Arrowsmith, Tim Carver, Nicholas Peters, Ellen Adlem, Arnaud
359		Kerhornou, Angela Lord, Lee Murphy, Katharine Seeger, Robert Squares, Simon Rutter,
360		Michael A Quail, MariAdele Rajandream, David Harris, Carol Churcher, Stephen D Bentley,
361		Julian Parkhill, Nicholas R Thomson and Matthew B Avison. The complete genome,
362		comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism
363		heavily shielded by drug resistance determinants [J]. Genome Biology, 2008, 9(4):
364	[21]	Reshma Amin VW. ntibiotic treatment for Stenotrophomonas maltophilia in people with
365		cystic fibrosis [J]. TheCochrane Library, 2012, 5.
366	[22]	Watson L, Esterly J, Jensen AO, et al. Sulfamethoxazole/trimethoprim versus fluoroquinolones
367		for the treatment of Stenotrophomonas maltophilia bloodstream infections [J]. J Glob
368		Antimicrob Resist, 2018, 12(104-106).
369	[23]	Liu W, Russel J, Roder HL, et al. Low-abundant species facilitates specific spatial organization
370		that promotes multispecies biofilm formation [J]. Environ Microbiol, 2017, 19(7): 2893-2905.
371	[24]	Liu W, Russel J, Burmolle M, et al. Micro-scale intermixing: a requisite for stable and
372		synergistic co-establishment in a four-species biofilm [J]. ISME J, 2018, 12(8): 1940-1951.
373		
374	[25]	Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium
	[25]	
375	[25] [26]	Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium
375 376		Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium [J]. Cell Host Microbe, 2019, 26(5): 569-570.
		Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium [J]. Cell Host Microbe, 2019, 26(5): 569-570.  Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn
376	[26]	Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium [J]. Cell Host Microbe, 2019, 26(5): 569-570.  Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn Children [J]. Cell, 2018, 174(5): 1277-1292 e1214.
376 377	[26]	Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium [J]. Cell Host Microbe, 2019, 26(5): 569-570.  Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn Children [J]. Cell, 2018, 174(5): 1277-1292 e1214.  Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and
376 377 378	[26] [27]	Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium [J]. Cell Host Microbe, 2019, 26(5): 569-570.  Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn Children [J]. Cell, 2018, 174(5): 1277-1292 e1214.  Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention [J]. Nat Med, 2017, 23(7): 859-868.
376 377 378 379	[26] [27]	Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium [J]. Cell Host Microbe, 2019, 26(5): 569-570.  Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn Children [J]. Cell, 2018, 174(5): 1277-1292 e1214.  Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention [J]. Nat Med, 2017, 23(7): 859-868.  Kondakova T, D'Heygere F, Feuilloley MJ, et al. Glycerophospholipid synthesis and functions in
376 377 378 379 380	[26] [27] [28]	Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium [J]. Cell Host Microbe, 2019, 26(5): 569-570.  Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn Children [J]. Cell, 2018, 174(5): 1277-1292 e1214.  Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention [J]. Nat Med, 2017, 23(7): 859-868.  Kondakova T, D'Heygere F, Feuilloley MJ, et al. Glycerophospholipid synthesis and functions in Pseudomonas [J]. Chem Phys Lipids, 2015, 190(27-42).
376 377 378 379 380 381	[26] [27] [28]	Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium [J]. Cell Host Microbe, 2019, 26(5): 569-570.  Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn Children [J]. Cell, 2018, 174(5): 1277-1292 e1214.  Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention [J]. Nat Med, 2017, 23(7): 859-868.  Kondakova T, D'Heygere F, Feuilloley MJ, et al. Glycerophospholipid synthesis and functions in Pseudomonas [J]. Chem Phys Lipids, 2015, 190(27-42).  Fang W, Li C, Wu Q, et al. Metabolic profiling of chronic obstructive pulmonary disease model
376 377 378 379 380 381 382	[26] [27] [28]	Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium [J]. Cell Host Microbe, 2019, 26(5): 569-570.  Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn Children [J]. Cell, 2018, 174(5): 1277-1292 e1214.  Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention [J]. Nat Med, 2017, 23(7): 859-868.  Kondakova T, D'Heygere F, Feuilloley MJ, et al. Glycerophospholipid synthesis and functions in Pseudomonas [J]. Chem Phys Lipids, 2015, 190(27-42).  Fang W, Li C, Wu Q, et al. Metabolic profiling of chronic obstructive pulmonary disease model rats and the interventional effects of HuaTanJiangQi decoction using UHPLC-Q-TOF/MS(E) [J].
376 377 378 379 380 381 382 383	[26] [27] [28] [29]	Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium [J]. Cell Host Microbe, 2019, 26(5): 569-570.  Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn Children [J]. Cell, 2018, 174(5): 1277-1292 e1214.  Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention [J]. Nat Med, 2017, 23(7): 859-868.  Kondakova T, D'Heygere F, Feuilloley MJ, et al. Glycerophospholipid synthesis and functions in Pseudomonas [J]. Chem Phys Lipids, 2015, 190(27-42).  Fang W, Li C, Wu Q, et al. Metabolic profiling of chronic obstructive pulmonary disease model rats and the interventional effects of HuaTanJiangQi decoction using UHPLC-Q-TOF/MS(E) [J].  J Pharm Biomed Anal, 2020, 180(113078).

386	[31]	Balany J and Bhandari V. Understanding the Impact of Infection, Inflammation, and Their
387		Persistence in the Pathogenesis of Bronchopulmonary Dysplasia [J]. Front Med (Lausanne),
388		2015, 2(90).
389	[32]	Wang X-H, Jia H-L, Deng L, et al. Astragalus polysaccharides mediated preventive effects on
390		bronchopulmonary dysplasia in rats [J]. Pediatric Research, 2014, 76(4): 347-354.
391		

Table 1 Demographic and clinical characteristics of the included patients

	Severe BPD	moderate BPD	mild BPD group	control group	P
	group (n=10)	group (n=5)	(n=10)	(n=5)	value
Gestational Age	30.46±2.18	32.54±1.35	31.76±1.54	31.57±0.61	0.138
$(\text{mean} \pm SD)$					
Birth weight (g)	1396.6±373.00	1530.0±363.67	1574±211.72	1640±139.10	0.421
$(\text{mean} \pm SD)$					
1 □ min	5.44±3.05	5.00±4.06	5.4±2.71	7.00±2.24	0.720
Apgar(mean ±					
SD)					
5 □ min Apgar	8(8-9)	8(7-9)	8.5(5-10)	9(8-9)	0.819
(median)					
10□min Apgar	9(8-9)	8(8-9)	9(8-10)	10(9-10)	0.148
(median)					
Male Gender n	5(50%)	4(80%)	4(40%)	1(20%)	0.274
(%)					
Han population, n	10(100%)	4(80%)	10(100%)	5(100%)	0.160
(%)					
Cesarean delivery,	5(50%)	5(100%)	8(80%)	5(100%)	0.069
n (%)					
Antenatal steroids,	7(70%)	2(40%)	7(70%)	3(60%)	0.664
n(%)					
Rupture of	1(10%)	1(20%)	1(10%)	1(20%)	0.902
membranes> 18					
hours, n (%)					
Intrauterine	1(10%)	1(20%)	0(0%)	0(0%)	0.444
growth restriction,					
n (%)					
Treatment with	7(30%)	2(40%)	8(80%)	3(60%)	0.466
surfactant, n (%)					
Mechanical	608	222	265	144	0.003
Ventilation hours					
(median)					
Oxygen days	6(0-36)	11(7-23)	14.5(12-20)	11(9-18)	0.720
Antibiotic days	39	16	23	14	0.011
(median)					
Pneumonia, n (%)	10(100%)	5(100%)	9(90%)	5(100%)	0.558
Pulmonary	5(50%)	2(40%)	3(30%)	0(0%)	0.272
hemorrhage, n (%)					
Late onset sepsis,	5(50%)	0(0%)	5(50%)	1(20%)	0.170
n (%)					
Necrotizing	0(0%)	0(0%)	1(10%)	0(0%)	0.558






Figure 1 Diversity and composition of the lower-airway microbiome

(a) Shannon index at birth (Day 1); (b) Shannon index on Day 7 after birth (a greater Shannon index is indicative of higher microbial diversity); (c) Principal coordinate analysis (PCoA) of microbial communities at birth (Day 1) (d) PCoA of microbial communities on Day 7 after birth (samples located close to each other have similar microbial compositions, samples at distant locations have distinct microbial compositions); (e-f) Relative abundance of bacterial phyla (birth [Day 1], e; 7 days after birth, f). (g-h) Relative abundance of bacterial genera (birth [Day 1], g; 7 days

after birth, h). (A, severe BPD [n=10]; B, moderate BPD [n=5]; C, mild BPD [n=10]; D, no BPD [n=5]).




Figure 2 Abundance of Stenotrophomonas

(a) The abundance of *Stenotrophomonas* at birth (Day 1), P < 0.05; (b) the abundance of *Stenotrophomonas* on Day 7 after birth, P=0.064. (A, severe BPD [n=10]; B, moderate BPD [n=5]; C, mild BPD [n=10]; D, no BPD [n=5]).




Figure 3: Metabolic profiles

(a-b) Principal Component Analysis (PCA) based on the metabolic profiles in sputum samples (birth [Day 1], a; 7 days after birth, b); (c-f) Hierarchical clustering heat maps showing patterns in molecular data across groups. The relative amounts of the 86 compounds were transformed into Z scores (birth [Day 1] ES-, c; ES+, d; 7 days after birth ES-, e, ES+, f). (A, severe BPD [n=10]; B, moderate BPD [n=5]; C, mild BPD [n=10]; D, no BPD [n=5]). ES+: positive ion mode, ES-: negative ion mode)




Figure 4: sn-Glycerol 3-phosphoethanolamine level at birth (Day 1)

\*:P < 0.05.




Figure 5: Scatter plot of the association between abundance of *Stenotrophomonas* and sn-glycerol 3-phosphoethanolamine level r=0.45, P<0.05.